{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:37:35Z","timestamp":1773160655880,"version":"3.50.1"},"reference-count":9,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Nephrol"],"published-print":{"date-parts":[[2004]]},"abstract":"<i>Background:<\/i> The renin-angiotensin-aldosterone system participates importantly in the progression of hypertensive renal disease. Angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists have been demonstrated to afford renoprotection in <i>L<\/i>-NAME-exacerbated nephrosclerosis in SHR rats. This study was designed to examine the effects of the aldosterone antagonist eplerenone on systemic and renal hemodynamics, glomerular dynamics, renal function and histopathology in <i>L<\/i>-NAME\/SHR, and determine whether aldosterone antagonism would enhance the effectiveness of ACE inhibition. <i>Methods:<\/i> Six groups of 20-week-old SHR were studied using renal micropuncture and histopathological techniques after 3 weeks of treatment: SHR control (tapwater, n = 10); SHR + eplerenone (101 \u00b1 8.3 mg\/kg\/day, n = 10); SHR + <i>L<\/i>-NAME (5.0 \u00b1 0.12 mg\/kg\/day, n = 9); SHR + <i>L<\/i>-NAME + eplerenone (n = 8); SHR + <i>L<\/i>-NAME + lisinopril (3 mg\/kg\/day, n = 9), and SHR + <i>L<\/i>-NAME + eplerenone + lisinopril (n = 9). <i>Results:<\/i><i>L<\/i>-NAME-treated SHR developed massive proteinuria, severe hypertensive nephrosclerosis, and tubulointerstitial damage. Eplerenone significantly reduced proteinuria (127.4 \u00b1 26.5 vs. 51.9 \u00b1 16.7 mg\/24 h, p < 0.01), improved glomerular and arteriolar injuries (65 \u00b1 9 vs. 29 \u00b1 9 score\/100 glomeruli, p < 0.01; 116 \u00b1 18 vs. 41 \u00b1 13 score\/100 arterioles, p < 0.01, respectively), and decreased tubulointerstitial damage index (1.43 \u00b1 0.07 vs. 0.39 \u00b1 0.07, p < 0.01) without altering mean arterial pressure or glomerular dynamics. Combined therapy of eplerenone with lisinopril produced no further benefits than lisinopril alone. <i>Conclusion:<\/i> The aldosterone antagonist eplerenone significantly ameliorated proteinuria and nephrosclerosis in the <i>L<\/i>-NAME\/SHR model, independent of hemodynamic effects.<\/jats:p>","DOI":"10.1159\/000077396","type":"journal-article","created":{"date-parts":[[2004,3,19]],"date-time":"2004-03-19T14:37:25Z","timestamp":1079707045000},"page":"242-249","source":"Crossref","is-referenced-by-count":58,"title":["Aldosterone Antagonism Ameliorates Proteinuria and Nephrosclerosis Independent of Glomerular Dynamics in <i>L<\/i>-NAME\/SHR Model"],"prefix":"10.1159","volume":"24","author":[{"given":"Xiaoyan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiko","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward D.","family":"Frohlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2004,4,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/snep.2001.26793"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/snep.2001.26794"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/en.141.10.3871"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200105000-00001"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ph.50.030188.002205"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000067463.13172.EA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000044937.95080.E9"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"}],"container-title":["American Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/77396","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/77396","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:21:22Z","timestamp":1745468482000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000077396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":9,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2004,4,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000077396","archive":["Portico"],"relation":{},"ISSN":["0250-8095","1421-9670"],"issn-type":[{"value":"0250-8095","type":"print"},{"value":"1421-9670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004]]}}}